PRODIGAL SONS: Li Chen, co-founder and CEO of Hua Medicine, at his office in Shanghai. The returnee start-ups are leveraging shifts in the global R&D landscape.
SHANGHAI: In biotech parks across the Yangtze River Delta, dozens of start-ups are working to develop drugs to treat China's biggest emerging diseases — from diabetes and Hepatitis B to respiratory illnesses and cancer.
It's early days, but firms like Hua Medicine and Innovent Biologics embody China's hopes for competitive biomedical innovation. And their Chinese-born, Western-educated founders represent the long-awaited return of the nation's brightest life scientists.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
